Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer

NCT03908671 | Unknown DMC

• 1 other identifier: STZD-1801
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

A single arm, open-label pilot study is designed to determine the safety, tolerability and effectiveness of personalized mRNA tumor vaccine encoding neoantigen in Patients with advanced esophageal cancer and non-small cell lung cancer

Conditions

Esophageal Cancer; Non Small Cell Lung Cancer

Keywords

mRNA cancer vaccine; cancer vaccine; tumor vaccine; NSCLC; Esophageal Cancer

Outcome Measures

Primary Outcomes (1)

• Number of participants with treatment-related adverse events as assessed by CTCAE v4.03

  During the trial conduction, especially within the 24 weeks of treatment phase when mRNA tumor Vaccine administered, all adverse events (including laboratory abnormality and clinical events) will be closely monitored, and all ≥ grade 3 adverse events per CTCAE will be recorded, including but not limited to the toxicities potentially suspected to relate to injection procedures and/or mRNA Tumor Vaccine therapy as listed below: Fever Chills Nausea, vomiting and other gastrointestinal symptoms Fatigue Hypotension Respiratory distress Tumor lysis syndrome Neutropenia, thrombocytopenia Liver and kidney dysfunction Neutropenia, thrombocytopenia Liver and kidney dysfunction

  24 weeks

Secondary Outcomes (4)

• Disease Control Rate (DCR)

  1.5 years

• Progression-free Survival (PFS)

  2 years

• Time to Tumor Progression (TTP)

  2 years

• Overall Survival (OS)

  3 years

Study Arms (1)

Personalized mRNA Tumor Vaccine

EXPERIMENTAL

Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients with advanced esophageal and non-small cell lung cancers

Biological: Personalized mRNA Tumor Vaccine

Interventions

Personalized mRNA Tumor Vaccine BIOLOGICAL

subcutaneous injection with personalized mRNA tumor vaccine

Personalized mRNA Tumor Vaccine

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged between 18 and 75 (including both ends), with no gender limit;
• The primary lesion was confirmed by histopathology or cytology as esophageal carcinoma (ⅢC (T4bNanyM0, TanyN3M0), and stage Ⅳ) or non-small cell lung cancer (stage ⅢB-Ⅳ).
• Patients who have metastatic or locally advanced tumor but failed instandard treatments or not suitable for standard treatments;
• According to RECIST (V1.1), the efficacy evaluation criteria for solid tumors, there is at least one measurable lesion.
• Participants with Performance Scale (PS) of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) PS
• Participants must have at least 1 lesion amenable to the mandatory fresh tumor biopsy at study entry
• Fertile patients must agree to use a reliable contraceptive methods (hormonal or barrier methods or abstinence) during the trial and for at least 12 weeks after the last treatment;
• The subject voluntarily participates and signs ICF (Informed consent forms).

You may not qualify if:

• Any clinical research drugs, anti-cancer monoclonal antibodies, anti-cancer therapeutic vaccines, immunostimulants (such as IL-2) or using previous investigational drugs within 7 days of the first treatment with mRNA-personalized tumor vaccine or carrelizumab.
• Patients who have allergies or previous history of biological drug allergy;
• Patients who are in pregnant or breast-feeding;
• Patients who are expected to survive less than 3 months during the screening period;
• Tumor mutation load (TMB) is less than 2.0/Mb or tumor neogenic antigen load (TNB) is less than 0.5/Mb or the number of predicted neoantigen is less than 3;
• Patients who underwent major surgery or suffered significant trauma within 4 weeks prior to the enrollment (blood collection), or who are expected to undergo major surgery during the study period;
• Patients with symptoms of brain metastases (Patients with stable brain metastases can be included)
• Extensive lung metastases from tumors, causing breathing difficulties;
• Patients who have tumors close to large blood vessels or nerves;
• A history of severe cardiovascular and cerebrovascular diseases, including but not limited to ventricular arrhythmia requiring clinical intervention; Acute coronary syndrome, myocardial infarction, congestive heart failure, stroke or other grade III and above cardiovascular events within 6 months; New York Heart Association (NYHA) cardiac function grade≥Grade II or left ventricular ejection fraction (LVEF) \<50%; Poorly controlled hypertension after standard treatment (systolic blood pressure\> 150 mmHg and diastolic blood pressure\> 90 mmHg);
• Patients with active ulcers and gastrointestinal bleeding;
• Patients with clinically confirmed autoimmune disease have received systemic treatment in the past 2 years; HIV, HCV positive; HBV-DNA≥1×103 copies/mL (or 2×102 IU/mL); Acute EBV or CMV virus infection;
• Patients with previous history of non-infectious pneumonia requiring steroid therapy or acute lung cancer;
• Participants with a history of interstitial lung disease;
• Patients who have a history of organ transplantation or are waiting for organ transplantation;

Sponsors & Collaborators

• Stemirna Therapeutics: lead
• The First Affiliated Hospital of Zhengzhou University: collaborator

Study Sites (1)

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

RECRUITING

MeSH Terms

Conditions

Esophageal Neoplasms; Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Head and Neck Neoplasms; Digestive System Diseases; Esophageal Diseases; Gastrointestinal Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Li Yang

CONTACT

0371-66295320; yanglizzuyl@163.com

Yi Zhang

CONTACT

0371-66295219; yizhang001@163.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 8, 2019
• First Posted: April 9, 2019
• Study Start: October 18, 2019
• Primary Completion: October 31, 2024
• Study Completion: December 31, 2025
• Last Updated: April 13, 2023

Record last verified: 2023-04

Locations

CN (1)